Tokyo, Japan – September 3, 2025 – Neusignal Therapeutics, Inc. (“NTX”), a Tokyo-based company focused on commercializing early-stage drug discovery from Tohoku University, today announced the completion of a dosing and safety/tolerability assessment in its First-in-Human (FIH) study of NTX-083, a drug candidate for Alzheimer’s disease. This investigator-initiated trial was conducted at the University of Tokyo Hospital, beginning on February 18, 2025. The study marked the first administration of NTX-083 to healthy volunteers, with the goal of evaluating the drug’s safety, tolerability, and pharmacokinetics.
With the completion of this study, NTX plans to initiate a company-sponsored multiple ascending dose study in healthy volunteers. In parallel, preparations are underway for a Phase 1b trial in Alzheimer’s disease patients in the United States.
Background
NTX is a startup dedicated to commercializing early-stage drug discovery from Tohoku University. The company’s lead compound, NTX-083, was selected for the third round of AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem. Development has been supported by Tohoku University Graduate School of Pharmaceutical Sciences, the AMED program, investors, and other stakeholders. NTX remains committed to accelerating the development of NTX-083 to address the unmet needs in Alzheimer’s treatment.
This research and development is supported by AMED under grant number JP25qfb127005, “Development of KATP channel inhibitor NTX-083 for Alzheimer’s disease therapy.”
Company overview
